Innovation in Drug Development Process Remains a Key Challenge, Tufts Center for the Study of Drug Development Says
October 20, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Oct 20, 2015) - Although pharmaceutical companies have long aspired to improve drug development efficiency, the drug development process remains highly inefficient and...
Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy, According to the Tufts Center for the Study of Drug Development
September 16, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 16, 2015) - Voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient, which could deny or limit patient access to...
Personalized Medicine Development Tied to Showing Value of Companion Diagnostics, Tufts Center for the Study of Drug Development Says
August 19, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 19, 2015) - With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show...
Vaccine Products in Development Have Tripled Over Last Decade, Tufts Center for the Study of Drug Development Study Says
July 09, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 9, 2015) - Vaccine products in the R&D pipeline have more than tripled since 2005 and annual worldwide sales are on track to reach $40 billion by 2020, according...
Personalized Medicine Is Gaining Traction, but Faces Multiple Challenges, Tufts Center for the Study of Drug Development Study Concludes
May 14, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 14, 2015) - While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of...
Biopharma Summit Set for May 12 on Re-Engineering Clinical Trials to Improve Drug Development and Performance
April 21, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 21, 2015) - Responding to the mounting challenges of highly inefficient and costly clinical trials, which have stymied R&D productivity, the Tufts Center for the...
Early BTD Projects Offer Lessons for Drug Companies, Tufts Center for the Study of Drug Development Says
April 14, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 14, 2015) - Flexibility and a willingness to learn from each other are key factors that enable drug companies and regulators to engage successfully in...
U.S. Biosimilar Approvals Poised to Grow, but Market Uptake Faces Several Challenges, According to the Tufts Center for the Study of Drug Development
March 05, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 5, 2015) - Biosimilar approvals in the United States are expected to increase during the next five years, but safety concerns among physicians and the need for...
Sponsors and CROs Implementing New Ways to Better Leverage Investigative Site Relationships, According to the Tufts Center for the Study of Drug Development
January 29, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 29, 2015) - Improved investigative site relationship use and effectiveness are top objectives in 2015 for pharmaceutical companies and contract research...
High Turnover and Protocol Noncompliance Continue to Plague the Global Investigative Site Landscape, According to the Tufts Center for the Study of Drug Development
January 15, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 15, 2015) - Global clinical trial performance and efficiency are hampered by high turnover and noncompliance among principal investigators and wide variation in...